eligibility_summary
Eligible: ≥80, or 65–79 and chemoimmunotherapy-ineligible, untreated, histologic DLBCL, stage II–IV, ECOG 0–2 without recent decline, ≥1 measurable lesion (≥10 mm by CT/MRI), adequate organ/marrow. Exclude: uncontrolled systemic disease, conflicting malignancy, active HBV/HCV/HIV, CNS lymphoma, CIRS-G single 4 or total >17, PML, significant infection, stroke/ICH <6 mo, bleeding diathesis, major surgery <30 d, warfarin use, live vaccine <28 d.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Acalabrutinib (CALQUENCE) – oral, small‑molecule, second‑generation covalent Bruton’s tyrosine kinase (BTK) inhibitor, Rituximab – anti‑CD20 chimeric monoclonal antibody (IV then SC). Mechanisms: Acalabrutinib selectively inhibits BTK within B‑cell receptor (BCR) signaling, suppressing downstream PLCγ2, NF‑κB, and PI3K/AKT pathways to reduce malignant B‑cell proliferation/survival and trafficking. Rituximab binds CD20 on B cells, triggering complement‑dependent cytotoxicity (CDC), antibody‑dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP), and apoptosis to deplete CD20+ lymphoma cells. Targets: CD20+ malignant B cells in DLBCL, BCR/BTK signaling axis, immune effector pathways (complement, NK cells/macrophages via Fcγ).